IP Library Granted Patent US 8,779,142
Granted Patent B2
US 8,779,142 · App. 13/378,527 · Granted Jul 15, 2014

Azabicyclo compound and salt thereof

Inventors: Makoto Kitade (Hanno, JP); Shuichi Ohkubo (Hanno, JP); Chihoko Yoshimura (Hanno, JP); Satoshi Yamashita (Hanno, JP); Hiromi Oshiumi (Hanno, JP); Takao Uno (Hanno, JP); Yuichi Kawai (Hanno, JP)
Assignee: Taiho Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,779,142
App. No.
13/378,527
Granted
Jul 15, 2014
Kind
B2
Abstract

It is intended to provide a novel azabicyclo compound which exhibits both HSP90 inhibitory activity and cell proliferation inhibitory effect. Specifically disclosed is a compound represented by the following general formula (I) or a salt thereof: wherein X 1 represents CH or N; any one of X 2 , X 3 and X 4 represents N, and the others represent CH; any one or two of Y 1 , Y 2 , Y 3 and Y 4 represent C—R 4 , and the others are the same or different and represent CH or N; R 1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S and O; R 2 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R 3 and R 4 represent —CO—R 5 or the like.

Claims (44)

1. A compound of formula (I)

or a salt thereof,

wherein:

X 1 is CH or N;

any one of X 2 , X 3 , and X 4 is N, and the others are CH;

any one or two of Y 1 , Y 2 , Y 3 , and Y 4 is C—R 4 , and the others are each independently CH or N;

R 1 is an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group comprising 1 to 4 heteroatoms selected from the group consisting of N, S, and O;

R 2 is a hydrogen atom, an optionally substituted alkyl group comprising 1 to 6 carbon atoms, or an optionally substituted alkenyl group comprising 2 to 6 carbon atoms;

R 3 is a cyano group or —CO—R 5 ;

each R 4 is independently a hydrogen atom, a halogen atom, a cyano group, an optionally substituted alkyl group comprising 1 to 6 carbon atoms, an alkenyl group comprising 2 to 6 carbon atoms, an alkoxy group comprising 1 to 6 carbon atoms, an aromatic hydrocarbon group, —N(R 6 )(R 7 ), —S—R 8 , or —CO—R 9 ;

R 5 is an amino group optionally comprising a hydroxyl group, or an optionally substituted mono- or di-alkylamino group;

R 6 and R 7 are each independently a hydrogen atom, an optionally substituted alkyl group comprising 1 to 6 carbon atoms, a halogenoalkyl group comprising 1 to 6 carbon atoms, an optionally substituted cycloalkyl group comprising 3 to 7 carbon atoms, an optionally substituted aralkyl group, an optionally substituted aromatic hydrocarbon group, an optionally substituted saturated heterocyclic group, or an optionally substituted unsaturated heterocyclic group,

or

R 6 and R 7 form a saturated heterocyclic group, together with the nitrogen atom to which they are bonded;

R 8 is an optionally substituted cycloalkyl group comprising 3 to 7 carbon atoms or an optionally substituted aromatic hydrocarbon group; and

R 9 is a hydrogen atom, a hydroxyl group, an amino group optionally comprising a hydroxyl group, or an optionally substituted mono- or di-alkylamino group,

wherein the optional substituents are selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a nitro group, an alkyl group, a halogenoalkyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aralkyl group, a hydroxyalkyl group, an alkenyl group, an alkenyl group, an alkoxy group, a halogenoalkoxy group, an alkoxy-alkyl group, a cycloalkoxy group, a cycloalkyl-alkoxy group, an aralkyloxy group, an aralkyloxy-alkyl group, an alkylthio group, a cycloalkyl-alkylthio group, an amino group, a monoalkylamino, dialkylamino group, a cycloalkyl-alkylamino group, an acyl group, an acyloxy group, an oxo group, a carboxyl group, an alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl group, a saturated heterocyclic group, an unsaturated heterocyclic group, an aromatic hydrocarbon group and a saturated heterocyclic oxy group;

with the proviso that if R 1 is substituted with the saturated or unsaturated heterocyclic group or the aromatic hydrocarbon group, the saturated or unsaturated heterocyclic group and the aromatic hydrocarbon group is optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a nitro group, an alkyl group, a halogenoalkyl group, a cycloalkyl group, a cycloalkylalkyl group, an aralkyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a halogenoalkoxy group, an alkoxy-alkyl group, a cycloalkoxy group, a cycloalkyl-alkoxy group, an aralkyloxy group, an aralkyloxy-alkyl group, an alkylthio group, a cycloalkyl-alkylthio group, an amino group, a monoalkylamino, dialkylamino group, a cycloalkyl-alkylamino group, an acyl group, an acyloxy group, an oxo group, a carboxyl group, an alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl group, a saturated heterocyclic group, an unsaturated heterocyclic group, an aromatic hydrocarbon group and a saturated heterocyclic oxy group.

2. The compound or salt of claim 1 , wherein R 1 is an optionally substituted monocyclic 5- to 6-membered unsaturated heterocyclic group comprising 1 to 3 heteroatoms selected from the group consisting of N, S, and O, or an optionally substituted bicyclic 9- to 10-membered unsaturated heterocyclic group comprising 1 to 3 heteroatoms selected from the group consisting of N, S, and O.

3. The compound or salt of claim 1 , wherein R 2 is an alkyl group comprising 1 to 6 carbon atoms optionally comprising a halogen atom, or an alkenyl group comprising 2 to 6 carbon atoms.

4. The compound or salt of claim 1 , wherein R 3 is —CO—R 5 , and R 5 is an amino group or a mono- or di-(C1-C6 alkyl)amino group.

5. The compound or salt of claim 1 , wherein X 2 is N, and X 3 and X 4 are CH.

6. The compound or salt of claim 1 , wherein R 1 is selected from the group consisting of an optionally substituted 1H-imidazol-1-yl group, an optionally substituted pyrazol-4-yl group, an optionally substituted thiophen-3-yl group, an optionally substituted furan-2-yl group, an optionally substituted pyridin-3-yl group, an optionally substituted pyridin-4-yl group, an optionally substituted indol-5-yl group, an optionally substituted 1H-pyrrolo[2,3-b]pyridin-5-yl group, an optionally substituted benzofuran-2-yl group, an optionally substituted quinolin-3-yl group, and an optionally substituted 5,6,7,8-tetrahydroquinolin-3-yl group.

7. The compound or salt of claim 1 wherein:

Y 1 and Y 3 are CH, any one or two of Y 2 and Y 4 are C-R 4 , and the other is CH; and

R 4 is a halogen atom, an alkyl group comprising 1 to 6 carbon atoms optionally comprising a mono- or di-(C1-C6 alkyl)amino group or a monocyclic 5- to 7-membered saturated heterocyclic group comprising one or two heteroatoms selected from the group consisting of N, S, and O, an alkoxy group comprising 1 to 6 carbon atoms, —N(R 6 )(R 7 ), —SR 8 , or —CO—R 9 .

8. The compound or salt of claim 1 , wherein:

R 6 is a hydrogen atom or an optionally substituted alkyl group comprising 1 to 6 carbon atoms, and R 7 is a hydrogen atom, an optionally substituted alkyl group comprising 1 to 6 carbon atoms, an optionally substituted cycloalkyl group comprising 3 to 7 carbon atoms, an optionally substituted aralkyl group comprising 7 to 12 carbon atoms, an optionally substituted aromatic hydrocarbon group comprising 6 to 14 carbon atoms, a monocyclic or bicyclic optionally substituted saturated heterocyclic group comprising 1 to 4 heteroatoms selected from the group consisting of N, S, and O, or a monocyclic or bicyclic optionally substituted unsaturated heterocyclic group comprising 1 to 4 heteroatoms selected from the group consisting of N, S, and O,

or

R 6 and R 7 form a 5- to 7-membered saturated heterocyclic group, together with the nitrogen atom to which they are bonded;

R 8 is an optionally substituted cycloalkyl group comprising 3 to 7 carbon atoms, or an optionally substituted aromatic hydrocarbon group comprising 6 to 14 carbon atoms; and

R 9 is a hydrogen atom, a hydroxyl group, an amino group or a mono- or di-(C1-C6 alkyl)amino group.

9. A pharmaceutical product comprising a compound or salt of claim 1 .

10. A pharmaceutical composition comprising a compound or salt of claim 1 , and a pharmaceutically acceptable carrier.

11. The compound or salt of claim 1 , which is selected from the group consisting of

(2-(hydroxycyclohexylamino)-4-{3-isopropyl-4-(4-(4-methoxyphenyl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide);

2-(4-Hydroxycyclohexylamino)-4-{3-methyl-4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-pyrazolo[2,3-b]pyridin-1-yl}benzamide;

4-{3-Isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl }-3-methylbenzamide;

3-Ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide;

3-(Ethylamino)-4-{4-(4-(4-(1-methyl -1H-pyrazol-4-yl)-1H-imidazol-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide;

2-(Ethylamino)-4-{4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide;

3-(Isopropylamino)-4-{4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide; and

a salt thereof.

12. A pharmaceutical composition comprising the compound or salt of claim 11 , and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2011
From: KITADE, MAKOTO; OHKUBO, SHUICHI; YOSHIMURA, CHIHOKO; YAMASHITA, SATOSHI; OSHIUMI, HIROMI; UNO, TAKAO; KAWAI, YUICHI
To: TAIHO PHARMACEUTICAL CO., LTD.
Reel/Frame 027409/0206 →
Priority Claims (1)
JP 2009-164196 · Jul 10, 2009 · national
Continuity (1)
Related Publication 20120108589A1 · May 3, 2012